Preclinical
Please check out the biopharma industry’s COVID-19 stories that are trending for May 25, 2021.
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
The Francis Crick Institute and the Latvian Institute of Organic Synthesis developed a new compound that blocks the life cycle of the mosquito-borne parasite that causes malaria.
Takeda has touted the potential of its Dengue vaccine for several years, and new long-term data reinforces the promise of the medication that could prevent the deadly mosquito-borne virus.
NGM Bio’s aldafermin failed to hit its primary endpoint in its Phase IIB trial because of that, the company decides to shift resources to other programs.
If approved, Takeda said Maribavir would become the first and only treatment indicated for CMV infection in refractory patients.
Two of Merck’s Phase III pediatric trials show 15-valent pneumococcal conjugate vaccine, V114, may be safe and effective in healthy children.
Eli Lilly’s SURPASS-4 trial program shows tirzepatide, significantly reduced blood glucose levels and body weight better than insulin glargine in adult patients with type 2 diabetes.
Companies have already begun their announcements of new clinical studies for various treatment settings in preparation for ASCO 2021.
The FDA further delays Iovance’s filing for its TIL therapy as it requests additional data on the treatment’s potency assays.
PRESS RELEASES